ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0082

Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)

Medha Barbhaiya1, Deanna Jannat-Khah1, Doruk Erkan1, Karen Costenbader2 and On Behalf of New APS Classification Criteria Development Case Collectors1, 1Hospital for Special Surgery, New York, NY, 2Brigham and Women's Hospital, Belmont, MA

Meeting: ACR Convergence 2021

Keywords: antiphospholipid syndrome, obesity, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Antiphospholipid Syndrome Poster (0069–0083)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Few studies have evaluated the role of environmental factors in APS. While antiphospholipid antibodies (aPL) may be induced by environmental stiumuli, e.g., viruses, cardiovascular disease and venous thromboembolism (VTE) risk factors may contribute to thrombosis in aPL-positive patients. In particular, we hypothesized that cigarette smoking and obesity might be risk factors for aPL positivity and thrombosis development based on previous literature. Using international multi-center data on patients referred for “suspected APS”, we tested the association of smoking and obesity with aPL positivity and thrombosis.

Methods: We collected 1216 cases of patients referred to 32 major centers in North America, South America, Europe, and Asia for suspected APS (aPL-positive/negative cases with/without history of thrombosis were collected as part of the new APS classification criteria development efforts, with additional questions specific for this project). Demographic, exposure, and clinical data were collected in a standardized format using an online secure REDCap database. For the current analysis, for each case, we also collected information related to current/past/never smoking history and most recent body mass index (BMI) at the office visit. We used t-tests or chi-square tests to evaluate associations of smoking (current versus former/never) and obesity (BMI≥ 30 versus < 30) with ever positive and most recent positive aPL (lupus anticoagulant [LA], anticardiolipin antibody [aCL] IgG, or anti-βeta-2-glycoprotein-I antibody [aβ2GPI] IgG) and with history of any thrombosis (including venous thromboembolism [VTE] or arterial thrombosis [AT]). aPL positivity was defined as test result above the laboratory normal range.

Results: Median age of 1216 cases was 42 years (IQR: 35, 55.5); 78.5% were female, 82.1% White, 10.4% Hispanic/Latinx, and 52.6% were European, and 37.7% North American. 64.2% of patients had positive LA tests, 42.9% had positive aβ2GPI IgG, and 53.6% had positive aCL IgG. 8.6% of patients were current smokers, while 22.8% had BMI≥ 30 kg/m2 at office visit (Table 1). We found no association of current smoking with history of ever or most recent positive LA, aCL IgG, aβ2GPI IgG as well as history of thrombosis overall, VTE, or AT (Table 2). However, obesity was associated with ever (but not most recent) positive LA (p=0.04) and history of thrombosis (p < 0.01), but not ever or most recent positive aCL or aB2GPI IgG positivity (Table 2). Obesity was specifically associated with VTE (p=0.01), but not AT.

Conclusion: Within a cohort of international cases referred for suspected APS, obesity was associated with a history of ever positive LA and with VTE. No clear association of current smoking was demonstrated, possibly due to low prevalence in our cohort. These results are hypothesis-generating and are being pursued in further analyses, accounting for potential confounders such as sociodemographics, concomitant systemic rheumatic disease, and other thrombosis risk factors. Subgroup analyses will evaluate also the association of these environmental stimuli with other aPL isotypes.


Disclosures: M. Barbhaiya, None; D. Jannat-Khah, Cytodyn, 12, own shares of stock, Walgreens, 12, Own stock shares, AstraZeneca, 12, own stock shares, GW Pharmaceuticals, 12, stock ownership; D. Erkan, ACR/EULAR, 5, LCTC, 5, NIH/NIAID, 5, GSK, 5, 6, Exagen, 5, Alexion, 2, UCB, 2, UpToDate, 9, APS ACTION, 4; K. Costenbader, Neutrolis, 11, Merck, Exagen, Gilead, 5, Astra Zeneca, Neutrolis, 2; O. Criteria Development Case Collectors, None.

To cite this abstract in AMA style:

Barbhaiya M, Jannat-Khah D, Erkan D, Costenbader K, Criteria Development Case Collectors O. Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/association-of-current-cigarette-smoking-and-obesity-with-antiphospholipid-antibodies-and-thrombosis-in-1216-international-patients-evaluated-for-suspected-antiphospholipid-syndrome-aps/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-current-cigarette-smoking-and-obesity-with-antiphospholipid-antibodies-and-thrombosis-in-1216-international-patients-evaluated-for-suspected-antiphospholipid-syndrome-aps/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology